Please assess the completion status of the following clinical trial:

Trial Title: Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, aged 18\~75 years old;~2. T2DM and treated with Metformin ≥ 1500mg/day constantly for at least 12 consecutive weeks;~3. 7.5% ≤ HbA1c ≤ 10.0% at screening;~4. 18.5 kg/m2 \< BMI \< 35.0 kg/m2 at screening;~Exclusion Criteria:~1. Any anti-diabetic therapy other than Metformin within 12 weeks before screening;~2. Received insulin therapy more than 30 days within 1 year before screening;~3. Fasting C-peptide \<0.81 ng/ml (0.27 nmol/L) at screening;~4. Medical history of severe hypoglycemia or frequent hypoglycemia, diabetic ketoacidosis, diabetes lactic acidosis or hyperosmotic nonketotic diabetic coma, severe cardio-cerebrovascular, unstable or rapidly progressive kidney disease, active liver diseases, diagnosed mental disease etc.~5. T1DM;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- HMS5552 (Type: EXPERIMENTAL): 75mg BID
- Placebo (Type: PLACEBO_COMPARATOR): BID

Based on this trial design, predict the completion outcome and termination type (if applicable).